article thumbnail

Revealed: pharma giants pour millions of pounds into NHS to boost drug sales

The Guardian - Pharmaceutical Industry

Drug firms are simultaneously funding groups that lobby for greater investment in their disease areas, and in some cases are paying generous consultancy fees to influential ­healthcare professionals, including GPs who have worked as clinical leads for NHS England and have received as much as £480,000 each from industry since 2019.

article thumbnail

Supplement Patient Care with a Registered Dietetic Technician Nutritionist

PioneerRx

According to Amina Abubakar in her most recent update, “As of 2019… More independent pharmacies are realizing that healthcare is undergoing a huge shift.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Digital health player UpHealth swells with three-way merger

pharmaphorum

The three-way deal combines UpHealth – which provides patient care management, telemedicine and digital pharmacy services and gives its name to the new group – with CloudBreak, which provides a video consultation platform for doctors and patients.

Packaging 138
article thumbnail

Amazon names 10 finalists in its first digital health accelerator

pharmaphorum

The finalists are: AIVA , a startup that has developed a voice operating system for patient care. In 2019, it acquired Health Navigator, a startup providing technology and services to digital health companies, to help power Amazon Care, a primary care programme offering employees virtual consultations.

Hospitals 138
article thumbnail

Combating the Healthcare Labor Crisis with Intelligent Infrastructure and the Autonomous Pharmacy

Omnicell

Despite the Omicron variant, patient volume for elective procedures is expected to rebound and surpass pre-pandemic levels. survey of 100 large private-sector hospitals, inpatient admissions are now back to 2019 levels on average and are expected to increase by 4 percent this year compared to 2019.

article thumbnail

Bad news for Pfizer as blockbuster Xeljanz flunks safety study

pharmaphorum

JAK inhibitor Xeljanz is one of Pfizer’s top-selling drugs, despite a ‘black box’ warning for blood clots and cancers added to its label in 2019. Now, a study designed to prove its safety has achieved the opposite. There were however warning signs all wasn’t well with the trial.

Labelling 135
article thumbnail

Microbiology Laboratory Strategies to Advance Antimicrobial Stewardship

IDStewardship

In 2019, The Lancet shared a systemic analysis that reported an estimation of 1.27 Medical Advisor, bioMérieux Chat participants also shared that institution-specific data resonate best with providers when it comes to prescribing and direct patient care. million deaths attributed to and 4.95